'Beneficial inflammation' may promote healing in pulmonary fibrosis

Inflammation has long been considered an integral part of the biological process that leads to deadly scarring in idiopathic pulmonary fibrosis. New research at National Jewish Health, however, suggests that a little inflammation may also be crucial to the healing and repair processes in the lungs. Elizabeth Redente, PhD, assistant professor of cell biology at National Jewish Health, and her colleagues report in the April 2014 issue of the American Journal of Respiratory Cell and Molecular Biology that the pro-inflammatory cytokine TNF-α can speed recovery of injured lungs and accelerate the resolution of established fibrosis in a mouse model.

"The role of in the development of scarring has been hotly debated in recent years," said Dr. Redente. "Our findings show for the first time that TNF-α actually promotes inflammation during the resolution of established scarring. A little inflammation may actually be a good thing in the right place and time."

Idiopathic is a relentless, progressive scarring of the lungs for which there is no approved medical therapy. The disease has no known cause and patients generally die within three years of diagnosis. Approximately 40,000 Americans die of every year.

Inflammation was long believed to be a precursor and cause of scarring in the lungs. However, anti-inflammatory treatments have shown no positive effect on the progress of the disease. In recent years, some researchers have thought that inflammation may be part of the healing process as well as the scarring of the lungs.

Dr. Redente and her colleagues gave mice TNF-α after their lungs had been injured and developed scar tissue. While these mice do normally heal from the lung injury, the researchers found that the TNF-α accelerated the recovery process. It reduced levels of collagen, the main component of scar tissue, and improved the flexibility of lung tissue well before the natural healing process would have begun. The researchers also found that knockout mice lacking the gene for TNF-α failed to heal as wild type mice eventually do.

The researchers believe that TNF-α acts by inducing white blood cells known as macrophages to change from ones that promote fibrosis to ones that promote inflammation instead. TNF-α may also promote the death of some of the pro-fibrotic macrophages.

"Physicians would welcome any therapy that could just slow down or stop the scarring process in the lungs," said David Riches, PhD, professor and head of the program in at National Jewish Health, and senior author on the study. "Our findings suggest that TNF-α not only slows the fibrotic process, but actually reverses established in the lungs."

The researchers are now investigating the role of TNF-α in various process that actually remove including the removal of collagen-producing cells, the degradation and removal of collagen and restoration of healthy cells.

add to favorites email to friend print save as pdf

Related Stories

Scarred lungs leave trail of beta arrestins

Mar 28, 2011

Targeting a family of signaling proteins called beta arrestins may stop the life-threatening scarring and thickening of lungs associated with pulmonary fibrosis, reports a new Science study in mice.

New clues on tissue scarring in scleroderma

Apr 18, 2014

A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma.

NOX4 implicated in fibrosis

Apr 11, 2014

Genkyotex, a developer of selective NOX enzyme inhibitors, announced today the publication of data showing that GKT137831, a first in class NOX1 and 4 inhibitor, was able to reverse lung fibrosis associated with aging in ...

Recommended for you

Phthalates heighten risk for childhood asthma

Sep 17, 2014

Researchers at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health are the first to demonstrate an association between childhood asthma and prenatal exposure to two phthalates used ...

ERS: Mepolizumab is glucocorticoid-sparing in asthma

Sep 09, 2014

(HealthDay)—For patients with eosinophilic asthma, mepolizumab has a glucocorticoid-sparing effect and reduces exacerbations when administered intravenously or subcutaneously, according to two studies published ...

User comments